| Comparative Trial of Entecavir Versus Adefovir in the Treatment of Chronic Hepatitis B Infection (NCT00096785) | Bristol-Myers Squibb | 2004-12-01 |
| Study of KOS-862 (Epothilone D) in Metastatic Prostate Cancer (NCT00104130) | Bristol-Myers Squibb | 2004-12-01 |
| Pharmacokinetics of Efavirenz in HIV-1 Infected Subjects With Hepatic Impairment (NCT00162097) | Bristol-Myers Squibb | 2004-11-01 |
| Effect of the Atazanavir (ATV) 150L Mutation on Subsequent Treatment Response in HIV Infected Subjects (NCT00096746) | Bristol-Myers Squibb | 2004-11-01 |
| A Phase I Study of BMS-275183 Given on a Daily Schedule in Patients With Advanced Malignancies (NCT00207025) | Bristol-Myers Squibb | 2004-10-01 |
| BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery (NCT00097357) | Bristol-Myers Squibb | 2004-10-01 |
| Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy for Patients With Moderate Hypertension (NCT00095550) | Bristol-Myers Squibb | 2004-10-01 |
| MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors (NCT00207103) | Bristol-Myers Squibb | 2004-09-01 |
| Effect of HIV Protease Inhibitor Drugs on Glucose and Insulin Metabolism (NCT00135434) | Bristol-Myers Squibb | 2004-09-01 |
| Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy as First Line Treatment for Severe Hypertension (NCT00095394) | Bristol-Myers Squibb | 2004-09-01 |
| A Study of Prevalence of the I50L Mutation When ATV Treated Patients Fail the Regimen (NCT00135447) | Bristol-Myers Squibb | 2004-09-01 |
| Irbesartan Versus Placebo in Combination With Ramipril for Treatment of Albuminuria (NCT00095290) | Bristol-Myers Squibb | 2004-09-01 |
| MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma (NCT00094653) | Bristol-Myers Squibb | 2004-09-01 |
| Vaccination Study of Abatacept (BMS-188667) for Normal Healthy Volunteers (NCT00279734) | Bristol-Myers Squibb | 2004-08-01 |
| Phase I (PH I) Mad Refractory Solid Tumor Study (NCT00099606) | Bristol-Myers Squibb | 2004-07-01 |
| Study of Boosted Atazanavir (ATV) Versus Non-boosted ATV in Naive Patients (NCT00084253) | Bristol-Myers Squibb | 2004-06-01 |
| A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder (NCT00095823) | Bristol-Myers Squibb | 2004-06-01 |
| Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma (NCT00084656) | Bristol-Myers Squibb | 2004-05-31 |
| Safety and Efficacy of Veronate® Versus Placebo in Preventing Nosocomial Staphylococcal Sepsis in Premature Infants (NCT00113191) | Bristol-Myers Squibb | 2004-05-01 |
| MAD Refractory: Solid Tumor QD w/o Break (NCT00207012) | Bristol-Myers Squibb | 2004-05-01 |
| Mechanism of Action and Efficacy of Muraglitazar in Type 2 Diabetes (NCT00094991) | Bristol-Myers Squibb | 2004-05-01 |
| Continue Entecavir Rollover From China (NCT00975091) | Bristol-Myers Squibb | 2004-05-01 |
| A Phase IIIb Study Comparing Two Boosted Protease Inhibitor-based HAART Regimens in HIV-infected Patients Experiencing Their First Virologic Failure While Receiving an NNRTI-containing HAART Regimen (NCT00135395) | Bristol-Myers Squibb | 2004-05-01 |
| To Assess Compliance With a Once-daily Regimen of Lamivudine, Efavirenz and Didanosine (NCT00207168) | Bristol-Myers Squibb | 2004-04-01 |
| A Pilot Study of Atazanavir/Ritonavir/Efavirenz as a Nucleoside Sparing Regimen (NCT00135343) | Bristol-Myers Squibb | 2004-04-01 |
| BMS-599626 in Patients With Advanced Solid Malignancies (NCT00095537) | Bristol-Myers Squibb | 2004-03-01 |
| A Comparison of Two Dose Levels of Didanosine Used in Combination With Stavudine in HIV-Infected Patients (NCT00002207) | Bristol-Myers Squibb | 2004-02-01 |
| Study Comparing Muraglitazar With Glimepiride in Type 2 Diabetics Who Are Not Controlled With Metformin Alone (NCT00095030) | Bristol-Myers Squibb | 2004-02-01 |
| A Study to Document Long-Term Safety and Continued Benefit of Irinotecan and Carboplatin or Irinotecan in Subjects With Refractory Solid Tumors (Rollover Study -001, -002) (NCT00990912) | Bristol-Myers Squibb | 2004-01-01 |
| Early Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Advanced or Recurrent Head and Neck Cancer (NCT01024101) | Bristol-Myers Squibb | 2004-01-01 |
| Study of HIV Patients With Undetectable Viral Load and Abnormal Lipids Switching to Atazanavir/Ritonavir (NCT00120393) | Bristol-Myers Squibb | 2004-01-01 |
| An Open-Label Rollover Study of Entecavir (BMS-200475) in Adults With Chronic Hepatitis B Infection (NCT01037062) | Bristol-Myers Squibb | 2003-12-01 |
| Effectiveness of KOS-862 in the Treatment of Lung Cancer (NCT00080509) | Bristol-Myers Squibb | 2003-12-01 |
| BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis (NCT00095173) | Bristol-Myers Squibb | 2003-12-01 |
| BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia (NCT00103701) | Bristol-Myers Squibb | 2003-11-01 |
| An Exploratory Study of Changes in Synovial Immune Responses Following BMS-188667 Therapy in Subjects With Active Rheumatoid Arthritis on Background DMARDs Who Have Failed Anti-TNF Therapy (NCT00162201) | Bristol-Myers Squibb | 2003-10-01 |
| A Study to Evaluate Combining Metformin With Muraglitazar or Pioglitazone in Type 2 Diabetics (NCT00240370) | Bristol-Myers Squibb | 2003-10-01 |
| Entecavir for Subjects With Chronic Hepatitis B Infection: An Early Access Program (NCT00096811) | Bristol-Myers Squibb | 2003-09-01 |
| A Phase II Dose Response Study in Japan in Chronic Hepatitis B (NCT01022801) | Bristol-Myers Squibb | 2003-08-01 |
| Comparison of Entecavir to Adefovir in Chronic Hepatitis B Virus (HBV) Patients With Hepatic Decompensation (NCT00065507) | Bristol-Myers Squibb | 2003-08-01 |
| PPAR-COMBO With Sulfonylurea (NCT00162175) | Bristol-Myers Squibb | 2003-07-01 |
| Study of MDX-010 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma (NCT00729950) | Bristol-Myers Squibb | 2003-07-01 |
| PPAR - Combination With Metformin (NCT00162240) | Bristol-Myers Squibb | 2003-06-01 |
| A Trial to Evaluate BMS-298585 as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control (NCT00246987) | Bristol-Myers Squibb | 2003-06-01 |
| Study of MDX-010 in Stage IV Breast Cancer (NCT00083278) | Bristol-Myers Squibb | 2003-05-01 |
| A Dose-Escalation Study of MDX-010 Administered Monthly as Immunotherapy in Subjects Infected With Human Immunodeficiency Virus (HIV) (NCT03407105) | Bristol-Myers Squibb | 2003-04-21 |
| A Study in Japan of the Safety and Antiviral Activity With Chronic Hepatitis B Infection (NCT01020565) | Bristol-Myers Squibb | 2003-02-01 |
| A Phase II Study of Carboplatin Plus Irinotecan Versus Irinotecan in Children With Refractory Solid Tumors (NCT00057473) | Bristol-Myers Squibb | 2003-02-01 |
| A Phase IIIb: Long-Term Outcomes for Hepatitis B (HepB) Patients in Some Previous Entecavir (ETV) Trials (NCT01337479) | Bristol-Myers Squibb | 2003-02-01 |
| Pravastatin Efficacy and Safety Trial in Hypercholesterolemic Patients With Chronic Liver Disease (NCT00529178) | Bristol-Myers Squibb | 2002-12-01 |
| A Phase III Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis (NCT00048932) | Bristol-Myers Squibb | 2002-12-01 |
| A Phase III Study of Abatacept (BMS-188667) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate (NCT00048568) | Bristol-Myers Squibb | 2002-12-01 |
| Study in Japan of the Safety And Antiviral Activity in Adults With Chronic Hepatitis B Current Lamivudine Therapy (NCT01037166) | Bristol-Myers Squibb | 2002-12-01 |
| Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Non-Small Cell Lung Cancer (NSCLC) (NCT01024062) | Bristol-Myers Squibb | 2002-12-01 |
| A Phase IIIB Study Evaluating the Effect on Serum Lipids Following a Switch to Atazanavir in HIV Infected Subjects Evidencing Virologic Suppression on Their First PI-Based Antiretroviral Therapy (NCT00067782) | Bristol-Myers Squibb | 2002-12-01 |
| Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past. (NCT00048581) | Bristol-Myers Squibb | 2002-12-01 |
| Comparison Study of MDX-010 (CTLA-4) Alone and Combined With Docetaxel in the Treatment of Patients With Hormone Refractory Prostate Cancer (NCT00050596) | Bristol-Myers Squibb | 2002-11-01 |
| Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Breast Cancer (NCT01023204) | Bristol-Myers Squibb | 2002-10-01 |
| Comparison Study of MDX-010 (CTLA-4) Alone and Combined With DTIC in the Treatment of Metastatic Melanoma (NCT00050102) | Bristol-Myers Squibb | 2002-10-01 |
| Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access (NCT01003990) | Bristol-Myers Squibb | 2002-10-01 |
| Study of Adding Entecavir to Current Lamivudine Therapy in HIV and HBV Co-Infected Patients (NCT00051038) | Bristol-Myers Squibb | 2002-09-01 |
| Comparability DE vs CD-CHO1 (NCT00277199) | Bristol-Myers Squibb | 2002-09-01 |
| Switching HIV-1 Infected Subjects From a Highly Active Anti-Retroviral Treatment (HAART) Regimen Dosed Twice Daily or More Frequently to a Once-Daily Regimen (NCT00135369) | Bristol-Myers Squibb | 2002-09-01 |
| Study Switching HIV-1 Infected Patients With an Undetectable Viral Load on a First Protease Inhibitor-Based Regimen to an Efavirenz-Based Regimen (NCT00135382) | Bristol-Myers Squibb | 2002-06-01 |
| Irbesartan in Heart Failure With Preserved Systolic Function (I-Preserve) (NCT00095238) | Bristol-Myers Squibb | 2002-06-01 |
| Atazanavir for HIV Infected Individuals: An Early Access Program (NCT00046345) | Bristol-Myers Squibb | 2002-05-01 |
| Dose Ranging Study With LT, Monotherapy, PPAR (NCT00240383) | Bristol-Myers Squibb | 2002-05-01 |
| Efficacy and Safety of BMS-298585 Alone or in Combination With Pravastatin in Subjects With Mixed Dyslipidemia (NCT00245388) | Bristol-Myers Squibb | 2002-04-01 |
| DART I - A Phase IV Study of 3 Antiretroviral Medicines in Combination, in HIV Patients Who Have Not Been Previously Treated With Antiretroviral Therapy (NCT00116415) | Bristol-Myers Squibb | 2002-03-01 |
| DART II - A Phase IV Study of 3 Antiretroviral Medicines in Combination, in HIV Patients Who Have Not Been Previously Treated With Antiretroviral Therapy (NCT00116116) | Bristol-Myers Squibb | 2002-03-01 |
| A Research Study to Assess the Mechanism By Which Glucovance, Metformin, and Glyburide Work To Control Glucose Levels In Patients With Type 2 Diabetes (NCT00035568) | Bristol-Myers Squibb | 2002-02-01 |
| A Phase III Study of Entecavir vs Lamivudine in Chronic Hepatitis B Subjects With Incomplete Response to Lamivudine (NCT00036608) | Bristol-Myers Squibb | 2002-01-01 |
| A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Positive for Hepatitis B E Antigen (NCT00035633) | Bristol-Myers Squibb | 2001-12-01 |
| A Research Study to Determine the Safety and Efficacy of Glucovance Compared to Metformin and Glyburide in Children and Adolescents With Type 2 Diabetes. (NCT00035542) | Bristol-Myers Squibb | 2001-12-01 |
| Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV (NCT00035932) | Bristol-Myers Squibb | 2001-11-01 |
| A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple Sclerosis (NCT00035529) | Bristol-Myers Squibb | 2001-11-01 |
| A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Negative for Hepatitis B e Antigen (NCT00035789) | Bristol-Myers Squibb | 2001-11-01 |
| A Trial to Evaluate Epothilone D in Patients With Advanced Solid Tumors (NCT00030173) | Bristol-Myers Squibb | 2001-10-01 |
| A Comparison of Atazanavir and Nelfinavir, Each in Combination With 2 NRTIs, in Patients Who Have Failed Treatments Without a Protease Inhibitor (NCT00028067) | Bristol-Myers Squibb | 2001-08-01 |
| Carboplatin and Irinotecan in Treating Children With Refractory Solid Tumors (NCT00024284) | Bristol-Myers Squibb | 2001-06-01 |
| An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection: Canada (NCT00162188) | Bristol-Myers Squibb | 2001-05-01 |
| Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney (NCT00035555) | Bristol-Myers Squibb | 2001-03-01 |
| Atazanavir Versus Lopinavir/Ritonavir (LPV/RTV) in Patients Who Have Not Had Success With Protease Inhibitor-Containing HAART Regimen(s) (NCT00028301) | Bristol-Myers Squibb | 2001-02-01 |
| A Comparison of BMS-232632 With Efavirenz, Each in Combination With Zidovudine-Lamivudine (NCT00013897) | Bristol-Myers Squibb | 2001-02-01 |
| BMS-247550 in Treating Patients With Metastatic Stomach Cancer Previously Treated With Chemotherapy (NCT00017043) | Bristol-Myers Squibb | 2001-02-01 |
| Rollover Study for Zerit (Stavudine) ER Studies (-096, -099) (NCT00116298) | Bristol-Myers Squibb | 2001-01-01 |
| Safety and Antiviral Activity of Entecavir in Participants With Chronic Hepatitis B Following Monotherapy in Other Entecavir Trials (NCT01438424) | Bristol-Myers Squibb | 2001-01-01 |
| Pravastatin or Atorvastatin Evaluation and Infection Therapy (TIMI22) (NCT00382460) | Bristol-Myers Squibb | 2000-11-01 |
| The Study of Abatacept in Combination With Etanercept (NCT00162279) | Bristol-Myers Squibb | 2000-10-01 |
| Abatacept With Methotrexate- Phase IIB (NCT00162266) | Bristol-Myers Squibb | 2000-10-01 |
| An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection (NCT00162227) | Bristol-Myers Squibb | 2000-09-01 |
| Study Comparing Weekly Taxol and Carboplatin vs Standard Taxol and Carboplatin Regimen for Stage IIIB or IV Non-Small-Cell Lung Cancer (NCT00035152) | Bristol-Myers Squibb | 2000-06-01 |
| Effectiveness and Safety of Two Forms of Stavudine in HIV-Infected Patients (NCT00005918) | Bristol-Myers Squibb | 2000-06-01 |
| A Phase I Study to Determine the Effect of Food on Brivanib (BMS-582664) (NCT00437437) | Bristol-Myers Squibb | 2000-05-01 |
| Safety and Effectiveness of a New Protease Inhibitor, BMS-232632, in HIV-Positive Patients Who Have Received Previous Treatment (NCT00004584) | Bristol-Myers Squibb | 1999-12-01 |
| Evaluation of an Anti-HIV Drug Combination That Includes a Coated Form of Didanosine (ddI EC) Compared to a Typical Anti-HIV Drug Regimen (NCT00002429) | Bristol-Myers Squibb | 1999-07-01 |
| Study of a New Protease Inhibitor, BMS-232632, in Combination With Other Anti-HIV Drugs (NCT00002240) | Bristol-Myers Squibb | 1999-03-01 |
| Comparison of Two Anti-HIV Regimens That Include One of Two Forms of Didanosine (ddI) (NCT00002224) | Bristol-Myers Squibb | 1999-03-01 |
| A Study Comparing Two Forms of Didanosine in HIV-infected Patients (NCT00002360) | Bristol-Myers Squibb | 1999-03-01 |
| A Comparison of Two Triple-Drug Combinations in Patients Who Have Never Been Treated With Anti-HIV Drugs (NCT00002411) | Bristol-Myers Squibb | 1998-03-01 |